180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders
GLOBE NEWSWIRE, 24 March 2021
180 Life Sciences Corp. (NASDAQ: ATNF, the “Company”), a clinical-stage biotechnology company with its lead indication in Phase 2b/3 clinical trial, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. Continue reading “Article: 180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders”
